US 12,295,966 B2
Compounds for treating and preventing extracellular histone mediated pathologies
Christopher Parish, Kingston (AU); Connor O'Meara, Newcastle (AU); Lucy Coupland, Chifley (AU); Benjamin Ju Chye Quah, Jeffabomberra (AU); Farzaneh Kordbacheh, Belconnen (AU); Anna Orlov, Narrabundah (AU); Anna Browne, Acton (AU); Ross Stephens, Stirling (AU); Gregory David Tredwell, Turner (AU); Lee Andrew Philip, Greenleigh (AU); Karen Knox, Ellen Grove (AU); Laurence Mark von Itzstein, Gilston (AU); Chih-Wei Chang, Upper Commera (AU); Anne Brüstle, Acton (AU); and David Anak Simon Davis, Acton (AU)
Assigned to The Australian National University, Acton (AU); and Griffith University., Nathan (AU)
Filed by The Australian National University, Acton (AU); and Griffith University, Nathan (AU)
Filed on Feb. 6, 2023, as Appl. No. 18/106,138.
Application 18/106,138 is a continuation of application No. 16/770,987, granted, now 11,628,179, previously published as PCT/AU2018/051337, filed on Dec. 14, 2018.
Claims priority of application No. 2017905024 (AU), filed on Dec. 15, 2017.
Prior Publication US 2023/0255992 A1, Aug. 17, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7028 (2006.01); A61K 31/7016 (2006.01); A61P 7/02 (2006.01); A61P 37/06 (2006.01)
CPC A61K 31/7028 (2013.01) [A61K 31/7016 (2013.01); A61P 7/02 (2018.01); A61P 37/06 (2018.01)] 12 Claims
 
1. A pharmaceutical composition comprising:
a compound; and
a buffer system,
wherein the compound is a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof, having the general structure of:

OG Complex Work Unit Chemistry
wherein:
R1 is a small uncharged glycosidically linked substituent selected from the group consisting of O—(C1-6)alkyl and S—(C1-6)alkyl,
R2 to R8 are each a sulfate group selected from the group consisting of O-sulfate, and a pharmaceutically acceptable salt thereof,
wherein the buffer system is selected from the group consisting of a phosphate buffer system, and citrate buffer system, and
wherein the pharmaceutical composition is buffered at a pH ranging from pH 7.1 to pH 7.6.